Lecanemab real-world treatment outcomes from cohort study in early Alzheimer's disease. (PubMed, J Alzheimers Dis Rep) - Oct 16, 2026 - "Six patients were safely transitioned from aducanumab to lecanemab treatment upon market withdrawal of aducanumab. In a real-world clinical practice setting, the lecanemab effectiveness and safety profile were similar to that observed in clinical studies."
HEOR • Journal • Real-world evidence • Alzheimer's Disease • CNS Disorders
|
|
Alyanna Ferrer; Justin Moon
|